CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Icahn School of Medicaine at Mount Sinai |
New York, New York, United States, 10029 |
Contact: Sundar Jagannath, M.B.B.S 212-241-7873 |
Principal Investigator: Sundar Jagannath, M.B.B.S |
Memorial Sloan Kettering Cancer Center |
New York, New York, United States, 10065 |
Contact: Sham Mailankody, MD 646-675-2278 |
Principal Investigator: Sahm Mailankody, MD |
Sarah Cannon Research Institution |
Nashville, Tennessee, United States, 37293 |
Contact: Jesus Berdeja, MD 844-482-4812 asksarah@sarahcannon.com |
Principal Investigator: Jesus Berdeja, MD |
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.